1. Home
  2. BXMT vs SUPN Comparison

BXMT vs SUPN Comparison

Compare BXMT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Mortgage Trust Inc.

BXMT

Blackstone Mortgage Trust Inc.

HOLD

Current Price

$18.18

Market Cap

3.1B

Sector

Real Estate

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$44.70

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXMT
SUPN
Founded
1966
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.0B
IPO Year
1998
2010

Fundamental Metrics

Financial Performance
Metric
BXMT
SUPN
Price
$18.18
$44.70
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$21.38
$61.60
AVG Volume (30 Days)
1.2M
571.0K
Earning Date
04-29-2026
05-05-2026
Dividend Yield
9.85%
N/A
EPS Growth
154.70
N/A
EPS
N/A
N/A
Revenue
N/A
$392,755,000.00
Revenue This Year
N/A
$22.70
Revenue Next Year
N/A
$19.14
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.67
$31.16
52 Week High
$20.67
$59.68

Technical Indicators

Market Signals
Indicator
BXMT
SUPN
Relative Strength Index (RSI) 47.64 42.48
Support Level $17.98 $43.67
Resistance Level $18.89 $46.79
Average True Range (ATR) 0.32 1.35
MACD 0.03 0.13
Stochastic Oscillator 47.06 54.00

Price Performance

Historical Comparison
BXMT
SUPN

About BXMT Blackstone Mortgage Trust Inc.

Blackstone Mortgage Trust Inc is an externally managed real estate finance company that originates, acquires, and manages senior loans and other debt or credit-oriented investments collateralized by or relating to commercial real estate in North America, Europe, and Australia. Its portfolio is composed of senior loans secured by high-quality, institutional assets located in main markets, and sponsored by experienced, well-capitalized real estate investment owners and operators. The group finances its investments in a variety of ways, including borrowing under secured credit facilities, issuing collateralized loan obligations, or CLOs, other securitization transactions, syndicating senior loans and/or participations, and other forms of asset-level financing.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: